GLENDALE, Calif., June 29, 2017 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed" or "the Company") (OTC: AMEH), an integrated population health management company, today announced its fiscal year 2017 financial results for the year ended March 31, 2017.

Financial Highlights for the Year Ended March 31, 2017:

  • Net revenue of $57.4 million, an increase of 30% as compared to $44.0 million in the comparable period of 2016.
  • Loss from operations of $10.5 million as compared to $7.3 million in the comparable period of 2016. The loss in FY 2017 was primarily driven by the Company's capital investment in its population health management infrastructure for its Next Generation ACO, legal and transactional expenses related to the pending merger with Network Medical Management, Inc., and costs related to the temporary use of locum tenens physicians for new hospitalist contracts.
  • As of March 31, 2017, the Company had total assets of $20.4 million, including cash and cash equivalents of $8.7 million.

Select Operational Highlights for Fiscal Year 2017 included:

  • In December 2016, the Company entered into a definitive merger agreement with Network Medical Management, Inc. ("NMM"), one of the largest healthcare Management Services Organizations (MSOs) in the United States. Under the terms of the merger agreement, NMM shareholders are expected to own 82% and ApolloMed shareholders are expected to own 18% of issued and outstanding shares of ApolloMed at closing, which is expected to be approximately 80% and 20% respectively on a fully diluted basis.
  • In January 2017, one of the Company's subsidiaries, APA ACO, Inc. was selected to participate in the Centers for Medicare & Medicaid Services' ("CMS") Next Generation ACO Model. APA ACO was approved to participate in the All-Inclusive Population-Based Payment ("AIPBP") track, which is the most advanced risk-taking payment model, and is the only Next Generation ACO in the country out of 44 which is participating in the AIPBP track.
  • In November 2016, an affiliate of the Company acquired Bay Area Hospitalist Associates ("BAHA"), a hospitalist, intensivist and post-acute care practice with a presence at four hospitals and several skilled nursing facilities in San Francisco. BAHA had previously been a variable interest entity of ApolloMed.

Status of the Pending Merger with Network Medical Management:

  • ApolloMed and NMM filed their premerger Hart-Scott-Rodino notifications with the Federal Trade Commission on June 7, 2017. This is one of the specified conditions to which closing of the merger is subject.
  • ApolloMed is working diligently on completing and filing the merger Form S-4 with the Securities and Exchange Commission ("SEC").
  • The merger is expected to be consummated in the second half of calendar year 2017.

Status of the Next Generation ACO:

  • APA ACO began operations on January 1, 2017 with 32,000 Medicare patients and is leveraging its risk-management infrastructure.
  • The AIPBP operations started on April 1, 2017 and have been generating approximately $9.3 million per month in revenues for APA ACO.
  • APA ACO has been paying Part A and Part B claims since April 2017.

"The shift from fee-for-service to value-based contracts is accelerating nationally," stated Warren Hosseinion, Chief Executive Officer of Apollo Medical Holdings.  "Our company is well-positioned to facilitate the adoption of valued-based contracting and the optimization of clinical and financial metrics across the entire continuum of care.  We believe there are very few companies who are delivering a comparable breadth of both clinical and advanced technology capabilities in population health management."

"We are pleased with our 30% year-over-year revenue growth while investing in two transformative corporate initiatives in FY 2017," stated Gary Augusta, Executive Chairman of Apollo Medical Holdings.  "We aim to be at the forefront of emerging U.S. healthcare models where companies provide high-quality clinical expertise and medical management at a cost-effective price.  We expect to provide more information in both our upcoming Q1 FY 2018 Form 10-Q and Form S-4 filings."

For more details on ApolloMed's 2017 fiscal year end results, please refer to the Company's 10-K filed with the U.S. Securities Exchange Commission and accessible at www.sec.gov.  

Unaudited Financial Tables

 

APOLLO MEDICAL HOLDINGS, INC.

UNAUDITED CONSOLIDATED BALANCE SHEETS






March 31,




2017



2016


 ASSETS









 Cash and cash equivalents


$

8,664,211



$

9,270,010


Accounts receivable, net of allowance for doubtful accounts of $475,080 and $601,000 at March 31, 2017 and 2016, respectively



5,506,472




3,392,941


 Other receivables



464,085




581,213


 Due from Affiliates



18,314




20,505


 Prepaid expenses and other current assets



269,168




293,828


Total current assets



14,922,250




13,558,497











 Deferred financing costs, net



-




37,926


 Property and equipment, net



1,205,139




1,247,973


 Restricted cash



765,058




530,000


 Intangible assets, net



1,904,269




2,353,212


 Goodwill



1,622,483




1,622,483


 Other assets



225,358




216,442


 TOTAL ASSETS


$

20,644,557



$

19,566,533











LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY









 Accounts payable and accrued liabilities


$

7,883,373



$

4,572,307


 Medical liabilities



1,768,231




2,670,709


 Convertible note payable, net of debt issuance cost of $161,000



4,829,000




-


 Lines of credit



62,500




188,764


Total current liabilities



14,543,104




7,431,780











 Note payable – related party



5,000,000




-


 Warrant liability



-




2,811,111


 Deferred rent liability



747,418




728,877


 Deferred tax liability



83,667




43,479


Total liabilities



20,374,189




11,015,247




















 MEZZANINE EQUITY









Series A Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series B Preferred stock); 1,111,111 issued and outstanding as of March 31, 2016, Liquidation preference of $9,999,999 at March 31, 2016



-




7,077,778











 STOCKHOLDERS' EQUITY









Series A Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series B Preferred stock); 1,111,111 issued and outstanding as of March 31, 2017, Liquidation preference of $9,999,999 at March 31, 2017



7,077,778




-


Series B Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series A Preferred stock) 555,555 issued and outstanding as of March 31, 2017 and 2016, Liquidation preference of $4,999,995 at March 31, 2017 and 2016



3,884,745




3,884,745


Common stock, par value $0.001; 100,000,000 shares authorized, 6,033,518 and 5,876,852 shares issued and outstanding at March 31, 2017 and 2016, respectively



6,033




5,876


 Additional paid-in capital



26,331,948




23,524,517


 Accumulated deficit



(37,654,381)




(28,684,565)


 Stockholders' deficit attributable to Apollo Medical Holdings, Inc.



(353,877)




(1,269,427)


 Noncontrolling interest



624,245




2,742,935


Total stockholders' equity



270,368




1,473,508


TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY


$

20,644,557



$

19,566,533


 

APOLLO MEDICAL HOLDINGS, INC.

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS






For The Years Ended March 31,




2017



2016









Net revenues


$

57,427,701



$

44,048,740


Costs and expenses:









Cost of services



48,735,537




34,000,786


General and administrative



18,583,372




16,962,687


Depreciation and amortization



645,742




351,396


Total costs and expenses



67,964,651




51,314,869











Loss from operations



(10,536,950)




(7,266,129)











Other income (expense) :









Interest expense



(82,905)




(542,296)


Gain (loss) on change in fair value of warrant and conversion feature liabilities



1,633,333




(408,692)


Gain on deconsolidation of variable interest entity



242,411




-


Loss on debt extinguishment



-




(266,366)


Other income



14,701




239,057


Total other income (expense), net



1,807,540




(978,297)











Loss before benefit from income taxes



(8,729,410)




(8,244,426)











Benefit from income taxes



(47,495)




(71,037)











Net loss



(8,681,915)




(8,173,389)











Net income attributable to noncontrolling interests



287,901




1,170,655











Net loss attributable to Apollo Medical Holdings, Inc.


$

(8,969,816)



$

(9,344,044)











Net loss per share:









   Basic and diluted


$

(1.49)



$

(1.79)











Weighted average shares of common stock outstanding:









   Basic and diluted



6,001,680




5,212,927


About Apollo Medical Holdings, Inc. (ApolloMed)

Founded in 2001 and headquartered in Glendale, California, ApolloMed is a leading integrated population health management company committed to providing exceptional multi-disciplinary care in the communities it serves.  ApolloMed is addressing the healthcare needs of its patients by leveraging its integrated healthcare delivery platform comprised of:  ApolloMed Hospitalists, APA ACO (Next Generation ACO), ApolloMed ACO (MSSP Accountable Care Organization), Maverick Medical Group (Independent Physician Association), Apollo Care Connect and Apollo Palliative Services. ApolloMed strives to improve medical outcomes with high-quality, cost-efficient care.  For more information, please visit www.apollomed.net

Forward Looking Statements

This press release contains certain forward-looking statements. These forward-looking statements, which are included in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, may involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results and performance in future periods to be materially different from any future results or performance suggested by the forward-looking statements in this press release. Although the Company believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that actual results will not differ materially from these expectations, and the Company disclaims any duty to update any forward-looking statements made by the Company. From time to time, these risks, uncertainties and other factors are discussed in the Company's filings with the Securities and Exchange Commission.

FOR MORE INFORMATION, PLEASE CONTACT:

Devin Sullivan


Gary Augusta

Senior Vice President

- or -

Executive Chairman

The Equity Group


Apollo Medical Holdings

(212) 836-9608


(818) 839-5200

dsullivan@equityny.com 


gaugusta@apollomed.net

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/apollo-medical-holdings-reports-30-revenue-growth-year-over-year-for-fiscal-year-end-2017-300481954.html

SOURCE Apollo Medical Holdings, Inc.